TY - JOUR
T1 - 68Ga-DOTATATE PET
T2 - Temporal variation of maximum standardized uptake value in normal tissues and neuroendocrine tumours
AU - Coura-Filho, George Barberio
AU - Hoff, Ana A.F.O.
AU - Duarte, Paulo S.
AU - Buchpiguel, Carlos A.
AU - Josefsson, Anders
AU - Hobbs, Robert F.
AU - Sgouros, George
AU - Sapienza, Marcelo T.
N1 - Funding Information:
This study was funded by FAPESP 13/03876-4 ‘Avaliação do uso do 68Ga-peptídeo análogo de somatostatina PET/ CT como ferramenta diagnóstica em tumores neuroendó-crinos e sua correlação com marcadores moleculares’.
Publisher Copyright:
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Objectives Higher affinity of 68Ga compounds to somatostatin receptors (SSTRs) and PET better image resolution increased interest in 68Ga-labelled somatostatin analogs in the management of neuroendocrine tumours (NETs). This study aimed to evaluate the maximum standardized uptake value (SUVmax) variation in sequential somatostatin analogs-PET in NET patients and identify optimal tumour detection and characterization imaging time. Methods Patients with histological or biochemical NET diagnosis performed two to three PET/computed tomography (CT) scans after intravenous injection of 68Ga-DOTATATE: Early PET [EarlyPET: <15 minutes postinjection (p.i.)], diagnostic PET (DiagPET: 45-90 minutes p.i.) and delayed PET (DelayPE: 90-240 minutes p.i.). Up to five tumour sites and normal tissues had SUVmax determined. Time-SUVmax curves were created for the target lesions and normal organs. Ratios between tumour and liver SUVmax (SUVTU/Liver) and tumour/blood pool (SUVTU/BP) were also calculated. Results Twenty-nine patients were included, 16 female, mean age of 46.5 ± 14.3 years. Average administered activity was 129.5 ± 29.6 MBq. Kidneys SUVmax was higher in EarlyPET compared with DiagPET (P = 0.04) and DelayPET showed higher SUVmax compared with DiagPET for normal liver, pancreas and kidneys (P = 0.02). No differences were noted between EarlyPET, DiagPET and DelayPET in tumour SUVmax (P > 0.05). SUVTU/Liver and SUVTU/BP did not change between EarlyPET and DiagPET, with a slight decrease in DelayPET. Conclusion Stability in tumour SUVmax values measured at different intervals independently of tumour location, as also in normal tissues as kidneys and liver suggest that a more flexible imaging protocol may be adopted.
AB - Objectives Higher affinity of 68Ga compounds to somatostatin receptors (SSTRs) and PET better image resolution increased interest in 68Ga-labelled somatostatin analogs in the management of neuroendocrine tumours (NETs). This study aimed to evaluate the maximum standardized uptake value (SUVmax) variation in sequential somatostatin analogs-PET in NET patients and identify optimal tumour detection and characterization imaging time. Methods Patients with histological or biochemical NET diagnosis performed two to three PET/computed tomography (CT) scans after intravenous injection of 68Ga-DOTATATE: Early PET [EarlyPET: <15 minutes postinjection (p.i.)], diagnostic PET (DiagPET: 45-90 minutes p.i.) and delayed PET (DelayPE: 90-240 minutes p.i.). Up to five tumour sites and normal tissues had SUVmax determined. Time-SUVmax curves were created for the target lesions and normal organs. Ratios between tumour and liver SUVmax (SUVTU/Liver) and tumour/blood pool (SUVTU/BP) were also calculated. Results Twenty-nine patients were included, 16 female, mean age of 46.5 ± 14.3 years. Average administered activity was 129.5 ± 29.6 MBq. Kidneys SUVmax was higher in EarlyPET compared with DiagPET (P = 0.04) and DelayPET showed higher SUVmax compared with DiagPET for normal liver, pancreas and kidneys (P = 0.02). No differences were noted between EarlyPET, DiagPET and DelayPET in tumour SUVmax (P > 0.05). SUVTU/Liver and SUVTU/BP did not change between EarlyPET and DiagPET, with a slight decrease in DelayPET. Conclusion Stability in tumour SUVmax values measured at different intervals independently of tumour location, as also in normal tissues as kidneys and liver suggest that a more flexible imaging protocol may be adopted.
KW - PET/computed tomography
KW - biokinetics
KW - gallium-68-DOTA
KW - neuroendocrine tumours
UR - http://www.scopus.com/inward/record.url?scp=85071351195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071351195&partnerID=8YFLogxK
U2 - 10.1097/MNM.0000000000001048
DO - 10.1097/MNM.0000000000001048
M3 - Article
C2 - 31343614
AN - SCOPUS:85071351195
SN - 0143-3636
VL - 40
SP - 920
EP - 926
JO - Nuclear medicine communications
JF - Nuclear medicine communications
IS - 9
ER -